Log in
Enquire now
‌

US Patent 10442867 Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy

Patent 10442867 was granted and assigned to Lentigen on October, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Lentigen
Lentigen
0
Current Assignee
Lentigen
Lentigen
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
104428670
Patent Inventor Names
Boro Dropulic0
Dina Schneider0
Rimas J. Orentas0
Date of Patent
October 15, 2019
0
Patent Application Number
160507540
Date Filed
July 31, 2018
0
Patent Citations Received
0
‌
US Patent 11944648 Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
0
Patent Primary Examiner
‌
Maria Marvich
0
Patent abstract

Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10442867 Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.